Biosynex has acquired Para’kito
Biosynex has acquired Para’kito, operated by Hong-Kong based Evergreen Land Ltd. The transaction includes assets and IP and the exclusive right to commercialize the brand in Europe, Africa and South America.
Created in 2005, Biosynex is a leading public health player in France and Europe. The group develops, manufactures and markets medical devices for screening, diagnosis and prevention. Biosynex is the French market leader in the design and distribution of rapid tests (RDT), commercialized in 90+ countries. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, resellers and department stores. In 2021, the group generated over US$400 million of sales.
Launched in 2008, Para’kito is the leading European brand in the prevention and care of mosquito bites. The company provides a complete range of anti-mosquito bracelets and sprays based on 100% natural formulas, with a proprietary technology, and distributed via two channels: pharmacies and e-commerce. Para’kito is present in more than 30 countries and supplies 5,000+ pharmacies in France. In 2021, the brand generated over US$7 million of sales in Europe.
Oaklins’ team in France acted as M&A advisor to Biosynex in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more